.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view calls for inclusion of patients along with MASLD and size of liver end results in cardio-- renal-- metabolic tests, when data suggest mechanistically tenable benefits and also medical safety and security-- and also summarizes considerations for trial style and governing approval.